Company
Headquarters: Salisbury South, SA, Australia
CEO: Mr. Scott Anthony Richards
A$493.4 Million
AUD as of Jan. 1, 2024
US$336.1 Million
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
AbbVie | $285.06 B |
Roche | $240.44 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Asia, and internationally. The company operates through four segments: Generic Products, Specialty Products, Metrics Contract Services, and Mayne Pharma International. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Mayne Pharma Group Limited has the following listings and related stock indices.
Stock: ASX: MYX wb_incandescent